Genomic Cancer Panel And Profiling Global Market Report 2025

The genomic cancer panel and profiling market size has grown strongly in recent years. It will grow from $9.47 billion in 2024 to $10.31 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. Growth during the historic period can be attributed to the rising global cancer burden, increased use in clinical trials, expansion of diagnostic infrastructure, growing awareness of genetic testing, and increased government and research funding.

The genomic cancer panel and profiling market size is expected to see strong growth in the next few years. It will grow to $14.37 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. Growth in the forecast period is expected to be driven by the expansion of liquid biopsy applications, growing use in early detection, the continued growth in tailored therapies, and an increase in companion diagnostics approvals. Key trends in the forecast period include the integration of AI and machine learning for genomic data interpretation, the development of multi-omics approaches, cloud-based genomic data storage and analysis, integration with electronic health records, and the expansion of next-generation sequencing (NGS) platforms.

The increasing incidence of cancer is expected to drive the growth of the genomic cancer panel and profiling market. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells in the body. The rising cancer incidence is primarily due to factors such as an aging population, which increases the risk of cancer as people live longer. Genomic cancer panels and profiling are used to identify genetic mutations and biomarkers, facilitating personalized treatment plans and improving early detection and disease monitoring. For example, in January 2024, the American Cancer Society reported that approximately 20 million new cancer cases were diagnosed globally in 2022, resulting in 9.7 million deaths. With population growth, the global cancer burden is projected to rise to 35 million cases by 2050. Therefore, the increasing incidence of cancer will drive the growth of the genomic cancer panel and profiling market.

Major companies in the genomic cancer panel and profiling market are focusing on technological innovations, such as next-generation sequencers, which enhance the accuracy, speed, and comprehensiveness of cancer diagnostics. Next-generation sequencers are advanced DNA sequencing technologies that allow for rapid, high-throughput analysis of genetic material to identify mutations and other genomic features. For instance, in April 2025, QIAGEN N.V., a Netherlands-based biotechnology company, launched QIAseq panels designed for next-generation sequencers. These panels enable comprehensive genomic profiling by analyzing over 700 genes, targeting both research and clinical applications to improve cancer diagnostics and treatment strategies.

In June 2023, Quest Diagnostics, a US-based clinical laboratory company, acquired Haystack Oncology, a biotech firm specializing in liquid biopsy technologies for early cancer detection and monitoring. The acquisition expands Quest Diagnostics' capabilities in liquid biopsy and cancer detection, enhancing its genomic testing offerings.

Major players in the genomic cancer panel and profiling market are Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Hologic Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, ARUP Laboratories, Tempus Labs, Genscript Biotech Corporation, NeoGenomics Inc., Foundation Medicine, Invitae Corporation, Guardant Health Inc., Caris Life Sciences, Fulgent Genetics, NanoString Technologies Inc., Genecast Biotechnology Co. Ltd, Burning Rock DX, HTG Molecular Diagnostics Inc., and Predictive Oncology Inc.

North America was the largest region in the genomic cancer panel and profiling market in 2024. The regions covered in genomic cancer panel and profiling report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the genomic cancer panel and profiling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Genomic cancer panel and profiling is a molecular diagnostic technique that simultaneously analyzes multiple genes to detect genetic mutations, alterations, or biomarkers linked to cancer. Its primary purpose is to guide personalized treatment decisions, predict disease progression, and enhance cancer diagnosis and monitoring.

The main tissue testing types in the genomic cancer panel and profiling market are solid tissue testing and liquid tissue testing. Solid tissue testing involves analyzing samples from solid tumors or organs to identify genetic mutations, biomarkers, or disease characteristics. Various technologies are employed in this process, including next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in-situ hybridization (FISH), immunohistochemistry (IHC), and others. Cancer panels used in this testing include both single-gene and multi-gene panels. These tests are applied in clinical and research settings, serving end users such as hospitals, research and academic institutes, clinical and diagnostic laboratories, among others.

The genomic cancer panel and profiling market research report is one of a series of new reports that provides genomic cancer panel and profiling market statistics, including the genomic cancer panel and profiling industry global market size, regional shares, competitors with the genomic cancer panel and profiling market share, detailed genomic cancer panel and profiling market segments, market trends, and opportunities, and any further data you may need to thrive in the genomic cancer panel and profiling industry. This genomic cancer panel and profiling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The genomic cancer panel and profiling market consists of revenues earned by entities by providing services such as genetic mutation analysis, companion diagnostic testing, cancer risk assessment, and screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The genomic cancer panel and profiling market also includes sales of targeted gene panels, companion diagnostic kits, sequencing platforms and instruments, bioinformatics software, and analysis tools. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.